Wegovy News & Analysis
5 articles
Market Mood
Novo Nordisk (NVO) high-dose Wegovy shows 27.7% weight loss
Novo Nordisk (NVO) announced that patients taking the high-dose 7.2-milligram version of Wegovy lost an average of 27.7% of their weight over 72 weeks in a recent trial. This data was presented at the European Congress on Obesity and could assist Novo in enhancing its competitive position against Eli Lilly's (LLY) Zepbound, which has shown weight loss of over 20%. The previous highest dose of Wegovy (2.4 mg) resulted in a 17% average weight loss. Approximately 25% of patients in the higher dose trial experienced early treatment response, achieving significant weight loss early in the treatment cycle.
Read More
Novo Nordisk (NVO) Q1 2026 Earnings Boosted by Wegovy Demand
Novo Nordisk (NVO) reported first-quarter revenue of 96.82 billion kroner, a 24% increase year-over-year, largely driven by sales of its Wegovy weight loss pill, which generated 2.26 billion kroner ($353.6 million) from 1.3 million prescriptions. The drugmaker has raised its full-year guidance, now projecting adjusted sales and operating profit to decline between 4% and 12% in constant-currency terms, improving from prior estimates. The CEO noted that Wegovy captures 65% of new U.S. prescriptions in its category. Despite prior challenges, the earnings report indicates a recovery and better growth prospects ahead.
Read More
Novo Nordisk (NVO) lifts 2026 outlook; shares surge as Wegovy drives growth
Novo Nordisk (NVO) has raised its 2026 revenue outlook substantially, attributing this increase primarily to the strong performance of its weight-loss drug, Wegovy. The company reported a 20% year-on-year increase in sales for the most recent quarter, reaching DKK 54 billion. Following this announcement, NVO shares experienced a notable surge in trading volumes, reflecting increased investor confidence. This revision implies positive implications for future earnings and market position, particularly in the growing obesity management sector.
Read More
Novo Nordisk (NVO) Stock Rises 6% After Strong Wegovy Sales Data
Novo Nordisk (NVO) raised its full-year 2026 profit guidance following better-than-expected sales of its Wegovy weight-loss pill, which reached 2.26 billion kroner in Q1, above estimates of 1.16 billion kroner. The company's shares increased by 6.3% in morning trading, following prior gains over 8%. Adjusted sales and profits are expected to decline between 4% and 12% on a currency-adjusted basis, improving from prior projections. First-quarter sales were reported at 96.8 billion kroner ($15.2 billion), with operating profit surging 65% to 59.6 billion kroner.
Read More
Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions
Novo Nordisk's (NVO) Wegovy pill, launched in early January, has seen over 600,000 prescriptions written within three months, including more than 3,000 in its first week. This surge reflects a growing demand for GLP-1 treatments as patients previously deterred by injection methods now gravitate towards the oral option. The pill is priced between $149 to $299 per month, which analysts attribute to its early success. Despite this positive start, Novo's stock price remains under pressure as competition from Eli Lilly's newly approved GLP-1 product, Foundayo, arises.
Read More